KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials. PMID 41791006 · J Clin Oncol · 2026-Apr-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H S B
严格 v3 独有 eligiblephase3_publication_type confirmed 2 Figure · 7 Panel · risk visible
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial. PMID 41734362 · J Clin Oncol · 2026-Apr-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial. PMID 41712876 · J Clin Oncol · 2026-Apr-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Bayesian adaptive randomization in the I-SPY2 sequential multiple assignment randomized trial. PMID 42053379 · Biometrics · 2026-Apr-09 The record describes the I-SPY2 SMART as a Phase 2 platform trial, not Phase III/IIIb. It is a methodology paper presenting a Bayesian adaptive randomization scheme, not a primary report of trial results with a time-to-event efficacy endpoint. The primary endpoint is pathological complete response (pCR), which is not a time-to-event outcome (OS, PFS, DFS, etc.). The intervention involves novel agents, but the paper focuses on the trial design and randomization algorithm, not on reporting specific drug intervention efficacy results. Therefore, it fails multiple key eligibility criteria: it is not a Phase III trial, lacks a time-to-event endpoint, is not a drug intervention efficacy result report, and is not an original formal trial result.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial. PMID 41966308 · J Hepatol · 2026-Apr-09 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial). PMID 41962942 · BMJ · 2026-Apr-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study. PMID 41956546 · J Immunother Cancer · 2026-Apr-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Survival after breast-conserving surgery and radiotherapy versus mastectomy: propensity score analyses within a randomized anaesthesiology trial. PMID 41954954 · Br J Surg · 2026-Apr-09 The record is a secondary analysis of survival outcomes from a randomized trial that compared anesthesia types, not a drug intervention. While the cohort is from a randomized trial and the endpoints are time-to-event efficacy outcomes (OS, BCSS), there is no drug-containing intervention, and the trial is not a Phase III/IIIb or Phase II/III oncology drug trial. Therefore, it does not meet the core eligibility criterion of a drug intervention in an oncology Phase III/IIIb or Phase II/III randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Function-preserving radical surgery for early-stage non-small cell lung cancer: A review of limited resection approaches. PMID 41642077 · Jpn J Clin Oncol · 2026-Apr-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Bayesian reanalysis to assess consistency of TALAPRO-2 results in the Japanese subgroup with metastatic castration-resistant prostate cancer. PMID 41543049 · Jpn J Clin Oncol · 2026-Apr-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia. PMID 41490515 · Blood · 2026-Apr-09 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 11 Panel · risk unclear
Clinical efficacy of apalutamide in Asian patients with metastatic castration-sensitive prostate cancer: Bayesian reanalysis of the TITAN trial. PMID 41450247 · Jpn J Clin Oncol · 2026-Apr-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Multicenter, Randomized, Double-Masked, Sham-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-on Corneal Crosslinking in Keratoconus Subjects 8 to 45 Years of Age: Baseline Endothelial Studies. PMID 41960981 · Cornea · 2026-Apr-08 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Associations Between Quality of Life and Disease Progression in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials. PMID 41956912 · Eur Urol Oncol · 2026-Apr-08 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901). PMID 41956861 · Eur Urol · 2026-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial. PMID 41952212 · J Hematol Oncol · 2026-Apr-08 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Palbociclib in the Treatment of HR+/ HER2- Advanced or Metastatic Breast Cancer in Australia: A Real-World Retrospective Analysis. PMID 41952090 · Asia Pac J Clin Oncol · 2026-Apr-08 The study is a non-interventional, retrospective cohort analysis. It is not a randomized controlled trial, and there is no evidence it is a Phase III or definitive trial, as it is a real-world observational study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial. PMID 41951687 · NPJ Breast Cancer · 2026-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial. PMID 41951647 · Nat Commun · 2026-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trials. PMID 41951251 · Lupus Sci Med · 2026-Apr-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Initial testing of a mobile app behavioral pain coping intervention for patients with cancer: Results of a pilot randomized controlled trial. PMID 41950509 · J Psychosoc Oncol · 2026-Apr-08 This is a pilot randomized trial in cancer patients, but it does not meet core eligibility criteria. It lacks a drug-containing intervention (interventions are behavioral pain coping via app or video). It does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as the focus is on feasibility, acceptability, and pain outcomes. It is not a Phase III/IIIb or definitive Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study. PMID 41946687 · Signal Transduct Target Ther · 2026-Apr-08 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 2 Panel · risk unclear
Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency. PMID 41955533 · J Clin Endocrinol Metab · 2026-Apr-07 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The PRINCE-BC trial: precision regional irradiation of nodal stations for clinical evaluation of high-risk pN0 breast cancer - a phase III, open-label, randomized controlled trial. PMID 41947078 · BMC Cancer · 2026-Apr-07 The record describes a Phase III randomized trial with a time-to-event primary endpoint (DFS) but the intervention is radiation therapy, not a drug. It is also a protocol/registration without reported results, not an original result report.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Infarct growth rate and tenecteplase benefit in ischemic stroke at 4.5 to 24 h without thrombectomy-A secondary analysis of the TRACE-III randomized trial. PMID 41944559 · Int J Stroke · 2026-Apr-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Blood Pressure Parameters and Risk of Cognitive Decline and Dementia in Type 2 Diabetes: Results From the ADVANCE Trial. PMID 41914351 · J Am Heart Assoc · 2026-Apr-07 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation: A Randomized Clinical Trial. PMID 41712219 · JAMA · 2026-Apr-07 The study is an oncology Phase 3 randomized trial comparing two radiation therapy regimens for brain metastases. It is eligible for oncology, human, randomized, and phase criteria. However, it is excluded because the intervention is non-drug (radiation therapy only) and the primary endpoint is a patient-reported symptom score change, not a time-to-event efficacy endpoint like OS, PFS, or DFS.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Botulinum Toxin Type A in the Treatment of Primary Axillary Hyperhidrosis:A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety in Chinese Patients. PMID 41553927 · Aesthet Surg J · 2026-Apr-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial. PMID 41092464 · Aesthet Surg J · 2026-Apr-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China. PMID 41950998 · J Thorac Oncol · 2026-Apr-06 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B. PMID 41945711 · Hepatology · 2026-Apr-06 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Progress in management of advanced clear-cell renal cell carcinoma. PMID 41941086 · Clin Transl Oncol · 2026-Apr-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Intratympanic Dexamethasone Efficacy in Preventing Cisplatin-induced Tinnitus: A Randomized Controlled Phase IIIB Clinical Trial. PMID 41940636 · Ear Hear · 2026-Apr-06 The study is a randomized, phase IIIB trial with a drug intervention in an oncology context, but the primary endpoint is the prevention of a toxicity (tinnitus), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP). Therefore, it does not meet the key criterion for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Development and implementation of personalized postoperative care plans for gynecological oncology patients under the precision medicine paradigm: strategies to enhance patient participation and self-management capacity. PMID 41937146 · World J Surg Oncol · 2026-Apr-06 The study is a randomized oncology trial reporting time-to-event efficacy outcomes (DFS, EFS) with Kaplan-Meier analysis and HR. However, it is ineligible because the intervention is a non-drug-only behavioral/digital care pathway, and the trial phase is not explicitly identified as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of albumin-bound paclitaxel combined with simvastatin in the second-line treatment of small cell lung cancer: a phase II randomized controlled trial. PMID 41937137 · BMC Med · 2026-Apr-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study. PMID 40090937 · Chin Med J (Engl) · 2026-Apr-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparative long-term sedation efficacy of remimazolam vs propofol in malignant patients with mechanical ventilation: an exploratory non-inferiority randomized study. PMID 41935116 · Sci Rep · 2026-Apr-04 The record does not meet the eligibility criteria. While it is an oncology, human, randomized, drug-intervention trial with original results, the required Phase III/IIIb or Phase II/III evidence is not established from the provided metadata. Furthermore, the primary endpoint is not a time-to-event efficacy endpoint (OS, PFS, etc.) suitable for Kaplan-Meier digitization.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Validating National Registry Data for Randomised Trials: Comparison of registry-derived cardiovascular events with and without adjudication in the BETAMI-DANBLOCK trial. PMID 41934630 · Eur Heart J Qual Care Clin Outcomes · 2026-Apr-04 The trial is a cardiovascular registry-based randomized trial for beta-blocker therapy in myocardial infarction patients, not an oncology study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Time of Administration, Fasting, and a Low-Carbohydrate Diet on Alpelisib-Associated Hyperglycemia and Efficacy: A Pilot Randomized Controlled Phase IIb Trial. PMID 41976378 · Cancers (Basel) · 2026-Apr-03 The trial is a Phase IIb randomized study (not Phase III/IIIb or Phase II/III) and its primary endpoint is an incidence rate (EAIR) of a safety/toxicity outcome (hyperglycemia), not a primary/key time-to-event efficacy endpoint like OS, PFS, etc. While efficacy is mentioned as a secondary endpoint, it is not defined as a time-to-event outcome in the abstract, nor are KM curves or HRs reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial. PMID 41937088 · Ann Oncol · 2026-Apr-03 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial. PMID 41934626 · J Natl Cancer Inst · 2026-Apr-03 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
The efficacy of combined bandage contact lens and nasal margin suture fixation in pterygium patients and its impact on inflammatory cytokines. PMID 41933093 · Sci Rep · 2026-Apr-03 The study is not an oncology trial; it investigates pterygium (a benign ocular surface condition) using surgical and suture techniques, not a drug intervention for malignant neoplasms. It lacks a primary time-to-event efficacy endpoint (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial. PMID 41932699 · BMJ Open · 2026-Apr-03 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Vaginal natural orifice transluminal endoscopic surgery versus laparoscopy for ovarian cystectomy: a prospective, open-label, randomized, non-inferiority pilot trial. PMID 41931151 · Arch Gynecol Obstet · 2026-Apr-03 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma. PMID 41959823 · medRxiv · 2026-Apr-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). PMID 41934038 · Eur Urol · 2026-Apr-02 The record is a letter to the editor responding to a previously published trial report. The title explicitly states 'Re:', and no abstract is provided to verify the necessary inclusion criteria. Therefore, it is not an original formal result report of a randomized trial.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Subarachnoid Hemorrhage: Clazosentan vs. Fasudil for Vasospasm Prevention (SAVIOR) Study: Study Protocol for a Prospective, Multicenter, Randomized Trial. PMID 41927991 · Neurocrit Care · 2026-Apr-02 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Association between screening duration and treatment outcomes in the clinical trials of ranibizumab and aflibercept for neovascular age-related macular degeneration. PMID 41927600 · Sci Rep · 2026-Apr-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial. PMID 41927289 · BMJ Open · 2026-Apr-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. PMID 41707170 · N Engl J Med · 2026-Apr-02 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed